Aarti Pharmalabs Limited — PPTs, 12-05-2025: Investor Presentation

1. Financial Highlights:

Aarti Pharmalabs reported consolidated revenue of INR 21,151 Mn, up 14.2% YoY. EBITDA rose 20.3% to INR 4,644 Mn, with margins expanding 112 bps to 21.96%. PAT increased 25.6% to INR 2,724 Mn, and PAT margin improved by 117 bps to 12.88%. Standalone revenue grew 17.9% to INR 17,714 Mn, with EBITDA up 23.2% and margins at 24.08%. A strong balance sheet shows consolidated assets of INR 29,064 Mn and net debt/equity at 0.19x. Consolidated EPS stood at INR 30.04, reflecting solid earnings growth.

2. Strategic Initiatives & Growth Drivers:

Capacity for Xanthine Derivatives is being increased from 5,000+ to 9,000+ MTPA, targeting a 20-25% global market share. Phase 1 reactor expansion at Atali greenfield site with 450+ kL capacity aims for FY26 commercialization. The CDMO/CMO segment anticipates 30-40% YoY revenue growth in FY26, backed by enhanced R&D and sales presence in US/EU. Investments in two solar power projects are expected to cover nearly half of power needs, boosting sustainability and cost efficiencies.

3. Business Developments:

Phase 1 facility at Atali is being commissioned to support CDMO and intermediates scale-up. Operations span six manufacturing units including three USFDA-approved sites, with recent expansions at Vapi and Tarapur. The IP portfolio features 58 patents filed and 50+ US DMFs approved. The CDMO project pipeline includes 60 projects—33 commercial and 27 under development.

4. Market Position & Competitive Advantage:

Aarti is India’s largest Xanthine Derivatives manufacturer, fully backward integrated and less dependent on China, benefiting from “China+1” sourcing trends. It holds around 15-20% of the global Xanthine market, aiming for 20-25%. Strong regulatory approvals (USFDA, EUGMP, EDQM) support leadership in HPAPIs and complex chemistries. Manufacturing capabilities include cryogenic reactors and continuous flow chemistry, enabling scale and flexibility.

5. Investor Implications:

Robust top-line and profit growth driven by capacity additions and CDMO scaling highlight positive growth potential. Diversified product mix and global reach mitigate market risks, while steady R&D investment (~INR 42 Cr, 5% of sales) supports innovation. Execution of new facilities and international market expansion will require monitoring, but current financial strength and margin improvement indicate strong business momentum and enhanced returns.